We investigated whether the Neurofibromatosis type-1(NF1) gene was of prognostic relevance to gastric cancer (GC) patients. Immunohistochemical staining of 160 matched GC tumor and adjacent normal tissue samples showed that 58.1% (93/160) of GC samples were NF1-positive as compared to 94.4% (151/160) of normal tissue samples (χ 2 =58.05, P <0.001). qRT-PCR analysis revealed that NF1 mRNA expression is lower in GC tissues than normal tissues (χ 2 =34.23, P <0.001). Moreover, NF1 protein and mRNA levels were associated with T stage (P <0.05) and TNM (P <0.001). No association was observed with other clinicopathological parameters, including gender, age, tumor size, lymph-node metastasis, cancer differentiation and distant metastasis (all P >0.05). Kaplan-Meier analysis revealed that negative or low NF1 were associated with poor overall survival (OS) in gastric cancer patients (P<0.001). Further univariate and multivariate cox regression analysis also showed that NF1 expression was an independent risk factor of survival of GC patients. These data show that NF1 has prognostic relevance to clinical outcomes in gastric cancer patients.
INTRODUCTION
Gastric cancer (GC) is the third leading cause of cancer-related deaths and the fourth most common malignant tumors [1] . Most GC patients are diagnosed at an advanced stage with lymph nodes metastasis [2] . Most patients experience metastasis and recurrence after undergoing standard treatment that includes adjuvant chemoradiotherapy and surgery. Hence, the 5-year survival rate of GC is very poor [3, 4] . Therefore, new prognostic tumor markers and therapeutic targets are necessary to improve the clinical outcomes for GC patients.
Neurofibromatosis type-1(NF1) or von Recklinghausen disease is a common autosomal dominant condition affecting the nervous system with an estimated incidence of about 1 in 3,000-4,000 individuals worldwide [5, 6] . It is also a multi-system disease associated with many cancers [7, 8] . The NF1 gene is a classic tumor suppressor gene located on chromosome 17q11.2 and its product neurofibromin is an important negative regulator of Ras signaling pathway [9, 10] . Mutations in NF1 gene result in NF1 disease. Many studies have demonstrated that NF1 plays an important role in many cancers such as brain tumors [11] , breast cancer [12] , sporadic colon cancer [13] , lung cancer [14] , pheochromocytomas [15] and ovarian tumors [16] . Moreover, Vizcaino et al. demonstrated that glioma patients with low NF1 expression were associated with poor overall survival and diseasespecific survival [17] . In this study, we investigated the relationship between NF1 expression and clinicopathological characteristics of GC patients. Further, we analyzed the prognostic relevance of NF1 for GC patients.
RESULTS

NF1 protein expression in human gastric cancer tissues
First, we analyzed NF1 protein expression in 160 GC and paired non-cancerous tissues. We observed that the NF1 protein was mainly located in the cytoplasm. Its expression was higher in the normal gastric tissues (94.4%) compared to GC tissues (58.1%) ( Figure 1 .
Relation between NF1 protein expression and clinicopathological features
We further divided the 160 cancer tissues into high, low and negative NF1 protein expression groups and assessed the correlation between NF1 expression and clinicopathological characteristics. Our data demonstrated that NF1 expression was associated with T stage (χ 2 =15.36, P=0.018) and TNM stages (χ 2 =27.39, P<0.001; Table 2 ). However, as shown in Table 2 , NF1 was not associated with gender (P=0.693), age (P=0.971), tumor size (P=0.959), lymph-node metastasis (P=0.667), cancer differentiation (P=0.489) and distant metastasis (p=0.966).
Relationship between NF1 protein expression and the prognosis of these gastric cancer patients
At the end of the five-year follow-up (median,45months), 48 out of 160 patients were alive. Among them, 36 patients that showed NF1 protein expression had better prognosis compared to 12 Figure 2A) . Furthermore, the log-rank test demonstrated that GC patients with low or negative expression of NF1 protein had a poorer prognosis than those with high NF1 expression (χ2=10.56, P=0.001).
Expression level of NF1 mRNA in human gastric cancer tissues
Next, we performed real time quantitative PCR (qRT-PCR) to compare NF1 mRNA levels in gastric cancer and matched adjacent normal tissues. NF1 mRNA could be detected in both or one of the cancerous and matched adjacent normal tissues, or alternatively, none of the cancerous and adjacent normal tissues. The interassay coefficient of variation was <15% (in log scale) for this assay in our laboratory. Therefore, a 10-fold (one log) difference was not caused by inter-assay variations and should be considered an authentic difference in NF1 expression levels. All cancer tissues were grouped into three groups: NF1 high , NF1 low and NF1 negative expression group, the cancer tissues were designated as negative expression when NF1 mRNA was undetectable in cancer samples, the cancer tissues were designed as low expression when NF1 mRNA was detectable but the level was 10-fold lower than that in the adjacent normal tissues, and the cancer tissues were designed as high expression when NF1 mRNA was detectable and the level was either higher than, equal to, or lower (but less than 10-fold difference) than that in the adjacent normal tissues.
The qRT-PCR results showed that 96.3% (154/160) normal and 72.5% (116/160) gastric cancer tissues demonstrated NF1 mRNA expression (Table 3 ; Figure 3A ). Our data showed that NF1 mRNA expression was significantly different between the gastric cancer and normal tissues (χ2=34.23, P<0.001). However, NF1 mRNA expression was similar among different differentiation groups (χ 2 =3.707, P>0.05; Figure 3B ). These data further confirmed the immunohistochemical analysis, demonstrating that NF1 was highly expressed in normal tissues compared to gastric cancer tissues.
Relation between NF1 mRNA expression and clinicopathological features
When we compared NF1 mRNA expression with different clinicopathological features, we found no significant differences in relation to gender (P=0.141), age (P=0.800), tumor size (P=0.980), lymph-node metastasis (P=0.217), differentiation (P=0.476) and distant metastasis (P=0.416). 
Relationship between NF1 mRNA expression and the prognosis of these gastric cancer patients
After a five-year follow-up, we found that patients with NF1 mRNA expression had better prognosis than those with negative NF1 mRNA expression (χ2=9.475, P=0.002). Furthermore, Kaplan-Meier analysis showed that patients with high NF1 mRNA expression had better overall survival than patients with low or negative NF1 mRNA expression (χ2=19.599, P<0.001; Figure 2B ). These results showed that high NF1 mRNA expression indicated better prognosis for GC patients.
NF1 expression was an independent variable closely related to patients' survival
Further univariate and multivariate cox regression analysis showed that NF1 expression (HR, 1.57, 95%CI: 1.216-2.025; P=0.001) was an independent risk factor of survival of GC patients. Meanwhile, T stage (HR, 1.56, 95%CI: 1.203-2.023; P=0.001) was also found to be significantly associated with GC patients' survival (Table 5) .
DISCUSSION
The NF1 gene is one of the largest genes in the human genome, located at chromosome 17q11.2 and having 60 exons spanning over 350kb of genomic DNA [18, 19] . Recent studies have shown that NF1 is a tumor suppressor that plays a critical role in many cancers [20, 21] . Mutations in NF1 also lead to abnormalities in the cardiovascular, musculoskeletal and nervous systems [22] . Moreover, Iyengar et al. demonstrated that differential expression of the NF1 isoforms was associated with cellular differentiation in ovarian epithelial cancer [23] . To our knowledge, the relationship between NF1 and GC is unknown. Therefore, we systematically evaluated the expression of NF1 in normal and cancer GC tissues and investigated its prognostic relevance in GC.
In the present study, immunohistochemical staining and qRT-PCR analysis demonstrated that NF1 protein and mRNA levels were significantly reduced in GC cancer tissues compared to normal tissues. Immunohistological staining showed that 94.4% normal tissue samples positively stained 
Figure 3: (A)
Relative NF1 mRNA levels in normal and GC tissues (*P < 0.05; **P < 0.01). (B) Relative NF1 mRNA levels in different GC differentiation stages (*P < 0.05; **P < 0.01). study showed that NF1 was an active regulator of GTPRas accumulation [26] . Also, loss of NF1gene lead to epithelial-mesenchymal transition (EMT), thereby implicating NF1 in tumorigenesis and cancer metastasis [27] . However, NF1 function in GC is unknown and needs to be investigated further.
Although our study demonstrated prognostic value of NF1 in GC patients, there are some limitations in our study. First, the gastric cancer sample size in our study is relatively small that may have introduced inherent bias. Hence, future studies with large-scale samples are necessary to confirm our findings. Second, we did not collect the disease free survival (DFS) data in our study, which could be influenced by the postoperative treatment and follow-up examinations. Third, we investigated NF1 gene expression in GC tissues and its association with patient prognosis. However, we did not investigate the mechanisms downstream of NF1. These mechanisms need to be deciphered in future investigations.
In conclusion, our study demonstrated that low or negative NF1 expression in human GC tissues was associated with higher TNM stage and poor five-year overall survival compared to those with high NF1 levels. These data indicated that NF1 was a potential prognostic indicator for the survival of GC patients.
MATERIALS AND METHODS
Patients and samples
The present study included primary gastric cancer specimens from 160 patients (104 males and 56 females), who underwent surgery at the Affiliated Hospital of Shandong Academy of Medical Sciences (Shandong, P.R. China) between August 2008 and June 2011. All patients in the present study were confirmed by pathological examination after surgery. The patients did not receive chemotherapy or radiotherapy before surgery. The clinical and pathological data of all patients was obtained by reviewing medical records and pathology reports. These included gender, age, tumor size, tumor differentiation, T stage, lymph node metastasis, distant metastasis, and tumor-node-metastasis (TNM) stage. Clinicopathological classification and staging was determined according to the criteria recommended by the American Joint Committee on Cancer (AJCC) [28] . The age of the participating patients ranged from 34 to 79 yrs (mean: 54 yrs). Normal tissue was also obtained from all patients and was at least 5cm away from the cancer tumors. Further, we obtained survival data from telephone or outpatient follow-ups. The last follow-up 
Immunohistochemical staining
The normal and cancer tissue samples from 160 patients were paraffin embedded and cut into 4μm thick slices for immunohistochemical staining. Immunohistochemical staining was performed using the streptavidin-peroxidase two-stage method. Briefly, the tissue sections were dewaxed, hydrated and subjected to antigen retrieval with EDTA. Next, the samples were incubated with the rabbit anti-NF1 antibody (1:200; CUSABIO BIOTECH CO. Ltd) at 4 o C overnight. This was followed by incubation with horseradish peroxidase-conjugated anti IgG antibody (1:1000; Santa Cruz, USA) for 45 min and three washes with PBS for 5 min each. Then, the samples were developed with diaminobenzidine solution for 3 min, washed briefly in running water, counter-stained with hematoxylin, dehydrated through a graded series of alcohol to xylene and sealed piece with a neutral gum. Negative control tissues were stained similarly except that the primary antibody was replaced with PBS.
RNA extraction and real-time quantitative PCR (qRT-PCR)
Total RNA was extracted from cancer and noncancerous tissues using Trizol (Invitrogen, USA) according to the instructions of the Reverse Transcription System kit (Vazyme Biotech, China). Reverse transcription was performed according to kit instructions followed by quantitative PCR using the Roche 480 II Real-Time PCR machine, and the real time PCR conditions and reaction mixture composition were showed in Tables 6 and 7 . All the gene expression levels were analyzed and calculated by using the 2-ΔΔCt method [29] . NF1 and β-Actin primers were purchased from Sangon Biotech Company. The primer sequences for NF1 were: forward, 5′-ACA CATGCAAAATGGGAACA-3′ and reverse, 5′-TGGGA CATTCGCCTCTTAAC-3′. The primer sequences for β-Actin were: forward, 5′-AGCGAGCATCCCCCAA AGTT-3′ and reverse, 5′-GGGCACGAAGGCTCAT CATT-3′.
Evaluation of NF1 immunohistochemical staining
Immunohistochemical stained tissue sections were observed and photographed with a light microscope (Carl Zeiss, Germany). NF1 was detected mainly in the cytoplasm of the normal and tumor cells. The NF1 immunohistochemical stained tissue sections were reviewed and assessed independently by three pathologists in a blinded manner and a consensus was reached for each score. Scoring was based on the percentage of stained tumor cells (1=< 10%; 2=11%-50%; 3=> 51%) in a given tumor sample and the intensity of cytoplasmic staining that was graded as negative (score 0), weak (score 1), moderate (score 2), or strong (score 3). The final NF1 staining scores were calculated as percentage x staining intensity. Hence, final scores were, score 0=value 0; score 1=value 1-3; score 2=value 4-6; score 3=value 7-9. Then, the tissue sections were divided into two groups, low NF1 (score 0 or 1) and high NF1 (score 2 or 3) groups.
Statistical analysis
All data were statistically analyzed by SPSS version 17.0 software (SPSS Inc, Chicago, IL, USA). The Pearson's Chi-squared (χ 2 ) test was used to evaluate the difference between levels of NF1 staining in specimens and clinicopathological characteristics. The KaplanMeier survival analysis method was used to assess the association between NF1 expression and overall survival. The log-rank test was used to evaluate the differences between survival curve of patients with high or low NF1 expression. To determine prognostic factors, multivariate regression analysis was performed using the Cox proportional hazards model for variables with P<0.05 in the univariate Cox analyses. All P values were two-sided and a P value less than 0.05 were considered statistically significant.
